|
| 1 |
|
Conditions listed in this trial |
|
|
Neuroectodermal Tumor, Primitive |
|
|
Neuroepithelioma |
|
|
Osteosarcoma |
|
|
Sarcoma |
|
|
Sarcoma, Ewing's |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Neuroectodermal Tumors |
|
|
Neuroectodermal Tumors, Primitive |
|
|
Neuroectodermal Tumors, Primitive, Peripheral |
|
| 3 |
|
More general conditions related to this trial |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms, Bone Tissue |
|
|
Neoplasms, Connective and Soft Tissue |
|
|
Neoplasms, Connective Tissue |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplasms, Neuroepithelial |
|
| 4 |
|
Additional drug interventions recognized in this trial |
|
|
Vincristine |
|
| 5 |
|
More general drug interventions related to this trial |
|
|
Antimitotic Agents |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Phytogenic |
|
|
Mitosis Modulators |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Pharmacologic Actions |
|
|
Therapeutic Uses |
|
|
Tubulin Modulators |
|
| 6 |
|
Sponsors listed in this trial |
|
|
National Cancer Institute (NCI) |
